Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 6,284 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 6,284 shares of Nurix Therapeutics stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total value of $78,927.04. Following the sale, the chief financial officer directly owned 37,592 shares in the company, valued at $472,155.52. The trade was a 14.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Houte Hans Van also recently made the following trade(s):

• On Thursday, October 30th, Houte Hans Van sold 3,130 shares of Nurix Therapeutics stock. The shares were sold at an average price of $12.80, for a total value of $40,064.00.

Nurix Therapeutics Stock Down 2.5%

Nurix Therapeutics stock traded down $0.32 during mid-day trading on Monday, hitting $12.62. 2,124,781 shares of the company’s stock traded hands, compared to its average volume of 1,858,191. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56. The firm has a 50 day moving average price of $9.79 and a 200 day moving average price of $10.66. The company has a market cap of $970.23 million, a PE ratio of -4.25 and a beta of 2.30.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, October 9th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.19). Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%.The firm had revenue of $7.89 million during the quarter, compared to the consensus estimate of $16.06 million. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NRIX. Bank of New York Mellon Corp grew its holdings in shares of Nurix Therapeutics by 7.4% during the first quarter. Bank of New York Mellon Corp now owns 205,078 shares of the company’s stock valued at $2,436,000 after buying an additional 14,173 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Nurix Therapeutics by 8.7% during the first quarter. Arizona State Retirement System now owns 17,253 shares of the company’s stock valued at $205,000 after buying an additional 1,385 shares in the last quarter. New York State Common Retirement Fund grew its holdings in shares of Nurix Therapeutics by 148.6% during the first quarter. New York State Common Retirement Fund now owns 52,688 shares of the company’s stock valued at $626,000 after buying an additional 31,493 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new position in shares of Nurix Therapeutics during the first quarter valued at $499,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Nurix Therapeutics during the first quarter valued at $374,000.

Wall Street Analysts Forecast Growth

NRIX has been the topic of a number of research reports. Royal Bank Of Canada reissued an “outperform” rating and issued a $29.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, October 22nd. Baird R W raised Nurix Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Wednesday, October 8th. BTIG Research dropped their price objective on Nurix Therapeutics from $35.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, October 23rd. Finally, Wall Street Zen downgraded Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, October 11th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $26.73.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.